Full-Time

Scientist 1

New Product Development

Posted on 5/11/2026

LGC Group

LGC Group

1,001-5,000 employees

Sells oligos, probes, primers, viral materials

No salary listed

Portland, ME, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor’s degree in biology, Chemistry, or a related area
  • Knowledge of and ability to assess and understand clinical chemistry, toxicology and serology based IVD diagnostic tests and immunoassay systems.
  • Agreeable to work in BSL-2 laboratory and DEA regulated areas with personal protective equipment for handling potentially infectious or hazardous material
  • Experience with stage gate design control processes.
  • Strong organizational skills with ability to coordinate multiple projects to meet deadlines, solve problems, focus on priorities, and communicate effectively with all stakeholders.
  • Able to work independently and able to thrive in a fast-paced environment and adaptable to changes in development priorities.
  • Accurate and strong verbal and written communication skills with impeccable attention to detail.
  • Adept at statistical data analysis and articulating conclusions from data, raising issues with insight into implications based on data.
  • Flexible—able to work effectively in a variety of environments and situations.
  • Individual who actively seeks continuous learning and development
  • Able to accommodate <5% travel time, if necessary
Responsibilities
  • Proactively communicates upward and cross-functionally with colleagues to build relationships throughout the organization to clearly articulated goals and priorities.
  • Provide technical support for product development and manufacture of new products including IVD controls, reference materials, QC panels and other quality measurement tools.
  • Provide support for cross-site new product development.
  • Provide support for investigations and trouble-shooting activities, as needed, for technical manufacturing issues
  • Development of new product specifications and modification of existing specifications to ensure reliable and repeatable manufacturing. Products must be developed using LGC Clinical Diagnostics design control process to ensure compliance with CE and FDA guidelines.
  • Critically analyses data and communicates conclusions to the team.
  • Supports and assists in technical transfers of products into manufacturing.
Desired Qualifications
  • 5+ years experience in laboratory environment, product development or technical operations
  • Experience with working in BSL-2 laboratory. Experience with working in a DEA regulated laboratory.
  • Experience with basic and advanced laboratory techniques (i.e. pipetting, balance use, centrifugation, use of BSC hoods, safety procedures, etc.)
  • Experience with manufacture in a cGMP environment.
  • Familiarity with diagnostic and medical device requirements including ISO 13485.
  • Experience with serology and toxicology biomarkers preferred.
  • Familiarity with serological and toxicological test methods, platforms, and data analysis preferred.

LGC Group provides life-sciences tools and services worldwide, including oligo components, probes, primers, recombinant viral materials, and proficiency-testing schemes for food safety. Its products support vaccine development, diagnostics, and therapies through mass spectrometry, immunoassays, and nucleic acid chemistry. It differentiates itself with a broad catalog of high-quality tools plus global proficiency-testing services and a wide customer base across diagnostics, healthcare, and pharma. Its goal is to improve healthcare outcomes and help create safer vaccines and treatments by delivering reliable tools and quality services.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

1841

Simplify Jobs

Simplify's Take

What believers are saying

  • $100M Canada synthesis center opened September 9, 2025 boosts pharma capacity.
  • DiaMex acquisition on December 4, 2024 expands clinical diagnostics portfolio.
  • New Guildford labs strengthen UK measurement science leadership.

What critics are saying

  • New CEO Joydeep Goswami disrupts ChromaDex and DiaMex integrations.
  • Thermo Fisher undercuts LGC reference materials with cheaper solutions.
  • Canada center validation fails, causing 20-30% revenue shortfall.

What makes LGC Group unique

  • LGC leads in reference materials with ChromaDex acquisition on February 26, 2026.
  • LGC specializes in oligo components for vaccines against COVID-19 and Ebola.
  • LGC excels in proficiency testing for food safety and anti-doping via SSAS.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at LGC Group who can refer or advise you

Benefits

Hybrid Work Options

Remote Work Options

Company News

LGC Group
Feb 26th, 2026
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business

LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business. The acquisition further enhances LGC's ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence. London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC's reference materials offering and strengthens its commercial reach across North America. The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC's ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets. Bruno Rossi, EVP & General Manager, LGC Standards, said: "The ChromaDex standards portfolio further enhances LGC's ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC's position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains." For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best - advancing NAD+ science and delivering clinically proven, patented Niagen(R) solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders." The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC's commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World. LGC is a global leader in life sciences, diagnostics, and analytical solutions. LGC Group work with partners around the world to address some of society's most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health. Its science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, LGC Group provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions. With operations in 14 countries and more than 180 years of scientific expertise, its work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, its solutions are trusted by customers in more than 170 countries. For further information please contact: Customer contact: Richard Pembrey Sales Director, LGC Standards +1 603 851 2834 Media contact: Magda Bartoszewicz Director Corporate Brand and Communications, LGC Group +44 7408 850 514

CHEManager
Sep 12th, 2025
LGC Opens $100 Million Pharma Synthesis Center in Canada

LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, canada, significantly expanding global capacity for advanced research chemicals to support the pharmaceutical and life sciences sectors.

Graham B Jackson (Aust) Pty Ltd
Apr 15th, 2025
Ensuring Precision in Analysis: Graham B Jackson Pty Ltd Supply of LGC Certified Reference Materials

Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.

Health Technology Insights
Apr 4th, 2025
Laboratory Proficiency Testing Market to Reach $2.1 Billion by 2030

For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).

Investors in Healthcare
Jan 10th, 2025
UK: LGC appoints Joydeep Goswami as president and CEO

UK-based LGC, an international life sciences measurement and tools company, has appointed Joydeep Goswami as president and CEO, succeeding Euan O'Sullivan, who decided to step down from his role in early 2024 after fourteen years of service.